Advertisement: HCR mid banner
Advertisement: S-Tech mid banner 3
Advertisement: EBCam mid banner
Advertisement: Cambridge Network mid banner
Advertisement: Simpsons Creative
Advertisement: Wild Knight Vodka
Barr Ellison Solicitors – commercial property
Advertisement: CJBS mid banner
Advertisement: TTP
ARM Innovation Hub
Advertisement: Mogrify mid banner
Advertisement: Kao Data Centre mid banner
Advertisement: partnersand mid banner
Mid banner advertisement: BDO
Advertisement: RSM mid banner
3 April, 2019 - 11:26 By Kate Sweeney

Abcam forges US alliance with New Jersey contract research organisation

Abcam Cambridge Biomedical Campus

Abcam, the Cambridge life science reagents and tools specialist has unveiled a key collaboration with a US partner.

It has teamed with Visikol, a contract research organisation in New Jersey focused on advancing drug discovery, to develop new reagents and kits for improved tissue clearing and 3D imaging.

Tissue clearing methods, which are essential to get a better view of complex structures such as the brain and nervous system, have advanced the understanding of neuroscience. 

These methods are also being rapidly adopted into the drug discovery and safety toxicology fields, where it’s vitally important to characterise 3D cell culture models in their entirety.

Dr Tom Villani, chief scientific officer at Visikol, said: “Despite being an established technique, challenges such as antibody optimisation and labelling remain as tissue clearing requires the combination of several highly complex disciplines. 

“This collaboration addresses the industry need for improved tools to undertake rapid tissue clearing and 3D imaging that generates high-quality data.”

Newsletter Subscription

Stay informed of the latest news and features